<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Organon & Co — News on 6ix</title>
<link>https://6ix.com/company/organon-and-co</link>
<description>Latest news and press releases for Organon & Co on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Sun, 26 Apr 2026 23:51:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/organon-and-co" rel="self" type="application/rss+xml" />
<item>
<title>Sun Pharma signs Definitive Agreement to Acquire Organon</title>
<link>https://6ix.com/company/organon-and-co/news/sun-pharma-signs-definitive-agreement-to-acquire-organon</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/sun-pharma-signs-definitive-agreement-to-acquire-organon</guid>
<pubDate>Sun, 26 Apr 2026 23:51:00 GMT</pubDate>
<description>MUMBAI, India & JERSEY CITY, N.J., April 26, 2026--Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715) (together with its subsidiaries and/or associated companies, "Sun Pharma") and Organon & Co. (NYSE: OGN) ("Organon") today announced that they have entered into a definitive agreement under which Sun Pharma will acquire all outstanding shares of Organon for US$ 14.00 per share in an all‑cash transaction with an enterprise valuation of US$ 11.</description>
</item>
<item>
<title>Organon To Report First Quarter 2026 Results and Host Conference Call on May 7, 2026</title>
<link>https://6ix.com/company/organon-and-co/news/organon-to-report-first-quarter-2026-results-and-host-conference-call-on-may-7-2026</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-to-report-first-quarter-2026-results-and-host-conference-call-on-may-7-2026</guid>
<pubDate>Thu, 16 Apr 2026 11:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., April 16, 2026--Organon will release its first quarter 2026 financial results and host conference call on May 7, 2026.</description>
</item>
<item>
<title>Organon’s VTAMA® (tapinarof) cream, 1%, Granted Strong Recommendation in the 2026 American Academy of Dermatology Guidelines for Pediatric Atopic Dermatitis</title>
<link>https://6ix.com/company/organon-and-co/news/organons-vtamar-tapinarof-cream-1percent-granted-strong-recommendation-in-the-2026-american-academy-of-dermatology-guidelines-for-pediatric-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organons-vtamar-tapinarof-cream-1percent-granted-strong-recommendation-in-the-2026-american-academy-of-dermatology-guidelines-for-pediatric-atopic-dermatitis</guid>
<pubDate>Wed, 15 Apr 2026 11:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., April 15, 2026--VTAMA was the only steroid-free topical AAD found supported by high certainty of evidence across all severities in children 2 years and older with AD.</description>
</item>
<item>
<title>Organon accelerates Women's Health progress across Asia Pacific with 2026 Her Health Grants</title>
<link>https://6ix.com/company/organon-and-co/news/organon-accelerates-womens-health-progress-across-asia-pacific-with-2026-her-health-grants</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-accelerates-womens-health-progress-across-asia-pacific-with-2026-her-health-grants</guid>
<pubDate>Sun, 29 Mar 2026 22:31:00 GMT</pubDate>
<description>Organon Asia Pacific Cluster today announced the 2026 Her Health Grant recipients for the Asia Pacific region, marking a significant milestone in efforts to strengthen and expand women's health initiatives across the region.</description>
</item>
<item>
<title>Organon Debuts New Analysis of VTAMA® (tapinarof) cream, 1%, Phase 3 Pooled Data Demonstrating Early and Consistent Skin Clearance and Itch Improvement in Atopic Dermatitis Patients Down to 2 Years of Age</title>
<link>https://6ix.com/company/organon-and-co/news/organon-debuts-new-analysis-of-vtamar-tapinarof-cream-1percent-phase-3-pooled-data-demonstrating-early-and-consistent-skin-clearance-and-itch-improvement-in-atopic-dermatitis-patients-down-to-2-years-of-age</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-debuts-new-analysis-of-vtamar-tapinarof-cream-1percent-phase-3-pooled-data-demonstrating-early-and-consistent-skin-clearance-and-itch-improvement-in-atopic-dermatitis-patients-down-to-2-years-of-age</guid>
<pubDate>Fri, 27 Mar 2026 12:00:00 GMT</pubDate>
<description>JERSEY CITY, N.J., March 27, 2026--Organon's VTAMA (tapinarof) cream, 1% new Phase 3 pooled data analysis shows early and consistent skin clearance and itch improvements for AD patients</description>
</item>
<item>
<title>New Analysis of Organon’s VTAMA® (tapinarof) cream, 1%, Phase 3 Data Showed Early and Consistent Improvement in Patient-Reported Sleep Subdomains in Pediatric Patients Down to 2 Years of Age with Atopic Dermatitis</title>
<link>https://6ix.com/company/organon-and-co/news/new-analysis-of-organons-vtamar-tapinarof-cream-1percent-phase-3-data-showed-early-and-consistent-improvement-in-patient-reported-sleep-subdomains-in-pediatric-patients-down-to-2-years-of-age-with-atopic-dermatitis</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/new-analysis-of-organons-vtamar-tapinarof-cream-1percent-phase-3-data-showed-early-and-consistent-improvement-in-patient-reported-sleep-subdomains-in-pediatric-patients-down-to-2-years-of-age-with-atopic-dermatitis</guid>
<pubDate>Fri, 27 Feb 2026 13:00:00 GMT</pubDate>
<description>JERSEY CITY, N.J., February 27, 2026--Organon presents results from new VTAMA sub-analysis showing early and consistent improvement in atopic dermatitis patient-reported sleep subdomains.</description>
</item>
<item>
<title>Organon Enters into Agreement to License MIUDELLA®, Sebela Pharmaceuticals’ Hormone-Free Intrauterine Device</title>
<link>https://6ix.com/company/organon-and-co/news/organon-enters-into-agreement-to-license-miudellar-sebela-pharmaceuticals-hormone-free-intrauterine-device</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-enters-into-agreement-to-license-miudellar-sebela-pharmaceuticals-hormone-free-intrauterine-device</guid>
<pubDate>Mon, 23 Feb 2026 12:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., February 23, 2026--Organon (NYSE: OGN), a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, announced today that it has entered into an agreement to exclusively license global rights to MIUDELLA, Sebela Pharmaceuticals’ hormone-free copper intrauterine device (IUD) contraceptive. The effectiveness of this transaction is subject to review under the Hart-Scott-Rodino Antitrust Improvements Act and to U.S. Food and Dr</description>
</item>
<item>
<title>Organon Reports Results for the Fourth Quarter and Full Year Ended December 31, 2025</title>
<link>https://6ix.com/company/organon-and-co/news/organon-reports-results-fourth-quarter-123000172</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-reports-results-fourth-quarter-123000172</guid>
<pubDate>Thu, 12 Feb 2026 12:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., February 12, 2026--Organon announces Q4 2025 and Full Year 2025 earnings results, ending December 31, 2025.</description>
</item>
<item>
<title>Organon Launches Third Edition of Women's Health Accelerator Program Across Middle East, Turkey & Africa</title>
<link>https://6ix.com/company/organon-and-co/news/organon-launches-third-edition-womens-103400759</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-launches-third-edition-womens-103400759</guid>
<pubDate>Wed, 04 Feb 2026 10:34:00 GMT</pubDate>
<description>Organon has launched the third edition of its Women's Health Accelerator Program, expanding it to include the Middle East, Turkey and Africa (META). With support from Flat6Labs, the 2026 program will connect start-ups with regional investors for funding, market testing, and business model refinement.</description>
</item>
<item>
<title>Organon To Report Fourth Quarter and Full Year 2025 Results and Host Conference Call on February 12, 2026</title>
<link>https://6ix.com/company/organon-and-co/news/organon-report-fourth-quarter-full-123000848</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-report-fourth-quarter-full-123000848</guid>
<pubDate>Thu, 29 Jan 2026 12:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., January 29, 2026--Organon announces date for Q4 and FY2025 earnings results conference call will be February 12, 2026 at 8:30am EST.</description>
</item>
<item>
<title>Organon Completes Divestiture of JADA® System to Laborie</title>
<link>https://6ix.com/company/organon-and-co/news/organon-completes-divestiture-jada-system-174500502</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-completes-divestiture-jada-system-174500502</guid>
<pubDate>Wed, 28 Jan 2026 17:45:00 GMT</pubDate>
<description>JERSEY CITY, N.J., January 28, 2026--Organon announces the successful closing of the sale of its JADA® System to Laborie Medical Technologies Corp.</description>
</item>
<item>
<title>Organon Announces US Food and Drug Administration Approval of Supplemental New Drug Application Extending Duration of Use of NEXPLANON® (etonogestrel implant) 68 mg Radiopaque</title>
<link>https://6ix.com/company/organon-and-co/news/organon-announces-us-food-drug-021200007</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-announces-us-food-drug-021200007</guid>
<pubDate>Sat, 17 Jan 2026 02:12:00 GMT</pubDate>
<description>JERSEY CITY, N.J., January 17, 2026--Organon's NEXPLANON receives U.S. FDA sNDA approval for extended duration of use up to five years, including data for use in women with varying BMIs.</description>
</item>
<item>
<title>Organon Enters into a Commercialization Agreement for Daiichi Sankyo’s Nilemdo® in France, Denmark, Iceland, Sweden, Finland and Norway</title>
<link>https://6ix.com/company/organon-and-co/news/organon-enters-commercialization-agreement-daiichi-063000678</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-enters-commercialization-agreement-daiichi-063000678</guid>
<pubDate>Thu, 08 Jan 2026 06:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., January 08, 2026--Organon enters into agreement to expand access to a new, first-in-class treatment in certain European countries; builds on cardiovascular portfolio</description>
</item>
<item>
<title>TetraScience and Organon Collaborate to Modernize Quality Control Data Management</title>
<link>https://6ix.com/company/organon-and-co/news/tetrascience-and-organon-collaborate-to-modernize-quality-control-data-management</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/tetrascience-and-organon-collaborate-to-modernize-quality-control-data-management</guid>
<pubDate>Tue, 16 Dec 2025 15:15:00 GMT</pubDate>
<description>TetraScience, the Scientific Data and AI Company, announced that Organon LLC will deploy TetraScience's Scientific Data Foundry to modernize quality testing through automated scientific data workflows. This implementation supports Organon's mission to deliver life-changing medicines by improving quality control (QC) data management and streamlining batch release testing operations, initially at its Heist, Belgium manufacturing site.</description>
</item>
<item>
<title>Organon To Present at the Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/organon-and-co/news/organon-present-piper-sandler-37th-123000438</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-present-piper-sandler-37th-123000438</guid>
<pubDate>Tue, 25 Nov 2025 12:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., November 25, 2025--Organon's Interim CEO Joe Morrissey and CFO Matthew Walsh to participate in fireside chat at Piper Sandler Annual Healthcare Conference on December 3.</description>
</item>
<item>
<title>Henlius and Organon Announce US FDA Approval of POHERDY® (pertuzumab-dpzb), the First PERJETA (pertuzumab) Biosimilar in the US</title>
<link>https://6ix.com/company/organon-and-co/news/henlius-and-organon-announce-us-fda-approval-of-poherdyr-pertuzumab-dpzb-the-first-perjeta-pertuzumab-biosimilar-in-the-us-1</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/henlius-and-organon-announce-us-fda-approval-of-poherdyr-pertuzumab-dpzb-the-first-perjeta-pertuzumab-biosimilar-in-the-us-1</guid>
<pubDate>Mon, 17 Nov 2025 14:06:00 GMT</pubDate>
<description>Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced that the US Food and Drug Administration (FDA) has approved the Biologics License Application (BLA) for POHERDY® (pertuzumab-dpzb) 420 mg/14 mL injection for intravenous use, an interchangeable biosimilar to PERJETA (pertuzumab), for all indications of the reference product.[1] POHERDY is the first and only approved pertuzumab biosimilar in the US, representing an important milestone in expanding access to quality</description>
</item>
<item>
<title>Organon Reports Results for the Third Quarter Ended September 30, 2025</title>
<link>https://6ix.com/company/organon-and-co/news/organon-reports-results-third-quarter-123000473</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-reports-results-third-quarter-123000473</guid>
<pubDate>Mon, 10 Nov 2025 12:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., November 10, 2025--Organon (NYSE: OGN) today announced its results for the third quarter ended September 30, 2025.</description>
</item>
<item>
<title>New Data Show Early and Consistent Response to VTAMA® (tapinarof) Cream, 1%, in Children Aged 2+ with Atopic Dermatitis, Including Those With Associated Comorbidities</title>
<link>https://6ix.com/company/organon-and-co/news/data-show-early-consistent-response-130000612</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/data-show-early-consistent-response-130000612</guid>
<pubDate>Sat, 08 Nov 2025 13:00:00 GMT</pubDate>
<description>JERSEY CITY, N.J., November 08, 2025--Organon's VTAMA (tapinarof) cream, 1% shows early and consistent response in children 2+ with atopic dermatitis, including with atopic comorbidities.</description>
</item>
<item>
<title>Organon Announces Agreement to Divest its JADA® System for Up to $465 Million to Laborie</title>
<link>https://6ix.com/company/organon-and-co/news/organon-announces-agreement-divest-jada-123000603</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/organon-announces-agreement-divest-jada-123000603</guid>
<pubDate>Fri, 07 Nov 2025 12:30:00 GMT</pubDate>
<description>JERSEY CITY, N.J., November 07, 2025--Organon divests the JADA System for up to $465 Million to Laborie</description>
</item>
<item>
<title>Laborie Announces Agreement to Acquire the JADA® System from Organon</title>
<link>https://6ix.com/company/organon-and-co/news/laborie-announces-agreement-to-acquire-the-jadar-system-from-organon</link>
<guid isPermaLink="true">https://6ix.com/company/organon-and-co/news/laborie-announces-agreement-to-acquire-the-jadar-system-from-organon</guid>
<pubDate>Fri, 07 Nov 2025 12:30:00 GMT</pubDate>
<description>Leading diagnostic and therapeutic medical technology company Laborie Medical Technologies Corp. ("Laborie") announced it has entered into an agreement with Organon, a global healthcare company with a mission to deliver impactful medicines and solutions for a healthier every day, to acquire the JADA® System, an innovative FDA-cleared device for the rapid control and treatment of abnormal postpartum uterine bleeding or hemorrhage, when conservative management is warranted. The JADA System has lau</description>
</item>
</channel>
</rss>